Drug Approval | September 19, 2024
Lupin receives USFDA approval for Bumetanide Injection
Bumetanide Injection USP (RLD Bumex) had estimated annual sales of USD 20 million in the U.S.
Bumetanide Injection USP (RLD Bumex) had estimated annual sales of USD 20 million in the U.S.
The primary objective was to evaluate safety and tolerability of Ropanicant in patients with MDD
Coupled with Shea Butter, Cocoa Butter, and Mango Butter, the balm provides deep hydration, ensuring lips remain soft, smooth, and well-moisturized throughout the day
Eugia Steriles receives EIR from USFDA for new injectable facility
Wacker Biotech will manufacture the active ingredients of MinervaX’s novel vaccine candidate
Aragen Life Sciences is the first Indian CRDMO to receive SBTi approval
MoU signed to drive digital transformation through strategic projects across all three business sectors of Merck
At 10 years, more than one-third (34.0%) of patients with advanced melanoma were alive after treatment with KEYTRUDA, compared to 23.6% of patients treated with ipilimumab
KEYTRUDA is the first and only immunotherapy-based regimen to show a statistically significant and clinically meaningful improvement in overall survival
Total investment incurred for setting up the new R&D Rs 250 crore
Subscribe To Our Newsletter & Stay Updated
